An advisory committee for the U.S. Food and Drug Administration recommended continued monitoring of Bayer’s birth control pill Beyaz, following a review that made note of serious “adverse events” connected with the pill – including five deaths.
The safety review was focused on Beyaz use for post-pubescent girls who haven’t yet reached adulthood, but included information that applied to both adolescent and ...
continue reading...